ID

32776

Descripción

Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin); ODM derived from: https://clinicaltrials.gov/show/NCT00708578

Link

https://clinicaltrials.gov/show/NCT00708578

Palabras clave

Versiones (1)
  1. 15/11/18 15/11/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

15 de noviembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 2 Diabetes Mellitus NCT00708578

Inglés

Eligibility Type 2 Diabetes Mellitus NCT00708578

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes for at least 6 months
Descripción

Non-Insulin-Dependent Diabetes Mellitus Disease length

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
treated with maximal, tolerable dose of metformin (≥ 1000mg/day) and sulfonylurea (glimepiride≥ 4 mg/day or equivalent dose of other su) for at least 3 months prior to the screening visit
Descripción

Metformin Maximum Tolerated Dose U/day | Sulfonylurea Maximum Tolerated Dose U/day | Glimepiride U/day

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0752079
UMLS CUI [1,3]
C0456683
UMLS CUI [2,1]
C0038766
UMLS CUI [2,2]
C0752079
UMLS CUI [2,3]
C0456683
UMLS CUI [3,1]
C0061323
UMLS CUI [3,2]
C0456683
7.0 < hba1c < 11 %
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
fasting serum c-peptide > 0.33 nmol/l
Descripción

Fasting C-peptide level

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2208720
bmi < 30 kg/m²
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
patients who is willing to monitor bg using smbg
Descripción

Blood Glucose Self-Monitoring Willing

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0005803
UMLS CUI [1,2]
C0600109
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
type 1 diabetes
Descripción

Diabetes Mellitus, Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011854
clinical evidence of active liver disease, or serum alt 3 times the upper limit of the normal range
Descripción

Liver disease | Alanine aminotransferase increased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2]
C0151905
serum creatinine: ≥ 1.5 mg/dl for males, ≥ 1.4 mg/dl for females
Descripción

Creatinine measurement, serum | Gender

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0079399
active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
Descripción

Proliferative diabetic retinopathy | Light Coagulation | Operative Surgical Procedures | Retinal Disease Unstable | Retinal Disease Rapidly progressive | Light Coagulation Required | Operative Surgical Procedures Required | Optic fundus observation Recommended

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0154830
UMLS CUI [2]
C0023694
UMLS CUI [3]
C0543467
UMLS CUI [4,1]
C0035309
UMLS CUI [4,2]
C0443343
UMLS CUI [5,1]
C0035309
UMLS CUI [5,2]
C1838681
UMLS CUI [6,1]
C0023694
UMLS CUI [6,2]
C1514873
UMLS CUI [7,1]
C0543467
UMLS CUI [7,2]
C1514873
UMLS CUI [8,1]
C0423377
UMLS CUI [8,2]
C0034866
history of alcohol or other substance abuse
Descripción

Substance Use Disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038586
pregnancy or not using contraceptive in childbearing aged women
Descripción

Pregnancy | Childbearing Potential Contraceptive methods Absent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
UMLS CUI [2,3]
C0332197
breast feeding women
Descripción

Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006147
history of hypersensitivity to the study drugs or to drugs with a similar chemical structure
Descripción

Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Chemical Structure Similar

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C0220807
UMLS CUI [2,4]
C2348205
treatment with any medication including corticosteroid or herbal medicines that can affect blood glucose level within 3 months prior to study entry except metformin and sulfonylurea.
Descripción

Pharmaceutical Preparations Affecting Blood glucose level | Adrenal Cortex Hormones | Medicinal Herbs | Exception Metformin | Exception Sulfonylurea

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0392201
UMLS CUI [2]
C0001617
UMLS CUI [3]
C0025125
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0025598
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0038766
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Descripción

Study Subject Participation Status | Considerations Additional

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0518609
UMLS CUI [2,2]
C1524062
Volver a la parte superior de la página

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00708578

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
type 2 diabetes for at least 6 months
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Metformin Maximum Tolerated Dose U/day | Sulfonylurea Maximum Tolerated Dose U/day | Glimepiride U/day
Item
treated with maximal, tolerable dose of metformin (≥ 1000mg/day) and sulfonylurea (glimepiride≥ 4 mg/day or equivalent dose of other su) for at least 3 months prior to the screening visit
boolean
C0025598 (UMLS CUI [1,1])
C0752079 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C0038766 (UMLS CUI [2,1])
C0752079 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0061323 (UMLS CUI [3,1])
C0456683 (UMLS CUI [3,2])
Hemoglobin A1c measurement
Item
7.0 < hba1c < 11 %
boolean
C0474680 (UMLS CUI [1])
Fasting C-peptide level
Item
fasting serum c-peptide > 0.33 nmol/l
boolean
C2208720 (UMLS CUI [1])
Body mass index
Item
bmi < 30 kg/m²
boolean
C1305855 (UMLS CUI [1])
Blood Glucose Self-Monitoring Willing
Item
patients who is willing to monitor bg using smbg
boolean
C0005803 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
Liver disease | Alanine aminotransferase increased
Item
clinical evidence of active liver disease, or serum alt 3 times the upper limit of the normal range
boolean
C0023895 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
Creatinine measurement, serum | Gender
Item
serum creatinine: ≥ 1.5 mg/dl for males, ≥ 1.4 mg/dl for females
boolean
C0201976 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Proliferative diabetic retinopathy | Light Coagulation | Operative Surgical Procedures | Retinal Disease Unstable | Retinal Disease Rapidly progressive | Light Coagulation Required | Operative Surgical Procedures Required | Optic fundus observation Recommended
Item
active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
boolean
C0154830 (UMLS CUI [1])
C0023694 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
C0035309 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C0035309 (UMLS CUI [5,1])
C1838681 (UMLS CUI [5,2])
C0023694 (UMLS CUI [6,1])
C1514873 (UMLS CUI [6,2])
C0543467 (UMLS CUI [7,1])
C1514873 (UMLS CUI [7,2])
C0423377 (UMLS CUI [8,1])
C0034866 (UMLS CUI [8,2])
Substance Use Disorders
Item
history of alcohol or other substance abuse
boolean
C0038586 (UMLS CUI [1])
Pregnancy | Childbearing Potential Contraceptive methods Absent
Item
pregnancy or not using contraceptive in childbearing aged women
boolean
C0032961 (UMLS CUI [1])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Breast Feeding
Item
breast feeding women
boolean
C0006147 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Chemical Structure Similar
Item
history of hypersensitivity to the study drugs or to drugs with a similar chemical structure
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0220807 (UMLS CUI [2,3])
C2348205 (UMLS CUI [2,4])
Pharmaceutical Preparations Affecting Blood glucose level | Adrenal Cortex Hormones | Medicinal Herbs | Exception Metformin | Exception Sulfonylurea
Item
treatment with any medication including corticosteroid or herbal medicines that can affect blood glucose level within 3 months prior to study entry except metformin and sulfonylurea.
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0392201 (UMLS CUI [1,3])
C0001617 (UMLS CUI [2])
C0025125 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C0025598 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0038766 (UMLS CUI [5,2])
Study Subject Participation Status | Considerations Additional
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
C0518609 (UMLS CUI [2,1])
C1524062 (UMLS CUI [2,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial